Armata Pharmaceuticals published a study detailing the structure of phage P7-1, part of their AP-PA02 cocktail targeting Pseudomonas aeruginosa infections in cystic fibrosis and bronchiectasis patients. Using advanced cryo-electron microscopy, the research uncovered how P7-1's unique tail fibers contribute to its stability and infection mechanism. This insight supports Armata's development of phage therapies as alternatives to antibiotics, with AP-PA02 showing promise in Phase 2 trials. The findings pave the way for engineering more effective and stable phage treatments against resistant bacterial infections.
STARLUX Airlines has introduced the AIRSORAYAMA Silver, the world's largest flying canvas, featuring a unique liquid-metal livery designed by Japanese artist Hajime Sorayama. The aircraft, an Airbus A350-1000, was unveiled in Toulouse and will be pil...
Stellar network validators will vote on July 8 to approve Protocol 27, known as Zipper, which introduces native authentication delegation and improves security by fixing replay vulnerabilities in Soroban smart contracts. This upgrade simplifies accou...
About $410 million in leveraged crypto positions were liquidated within 24 hours, driven mainly by Bitcoin and Ethereum losses. Long positions accounted for nearly 63% of liquidations, indicating traders betting on price rises were hit hardest. Howev...
The DeXe (DEXE) token has surged 17.5% in the last 24 hours, driven by a 201% increase in daily trading volume, signaling strong market confidence. Unlike other AI sector tokens, DeXe shows notable bullish momentum, supported by steady capital inflow...
Netflix is seeing more viewers abandon shows before the second season, driven by frequent cancellations, long waits between seasons, and content tailored more for algorithms than storytelling. The streaming giant's binge model, once revolutionary aga...
